Navigation Links
Litigation Predicted in Wake of FAA Ban of Chantix Use by Pilots and Air Traffic Controllers: Smoking Cessation Drug Target of Controversy
Date:5/22/2008

BIRMINGHAM, Ala., May 22 /PRNewswire/ -- A veteran pharmaceutical litigation attorney predicted today that pharmaceutical giant Pfizer will face lawsuits from individuals who claim to have been harmed by its popular smoking cessation drug Chantix. The FAA issued an immediate ban on the use of Chantix by pilots and air traffic controllers on May 21 after receiving an analysis of adverse events published by the Institute for Safe Medication. The report cites cases that allege Chantix may cause serious unintended side effects including loss of consciousness.

Kristian Rasmussen, a veteran pharmaceutical litigation attorney with the law firm Cory Watson Crowder & DeGaris said, "The magnitude of the health risks associated with Chantix is alarming - we are trying to determine whether the drug maker, Pfizer, failed to disclose information it may have had about adverse side effects." Rasmussen said his team, that includes pharmaceutical and medical experts along with attorneys, has been investigating reports of devastating side effects for more than year. "What we are finding is that the magnitude of the safety signal associated with using Chantix is alarming both in terms of severity of injury and the number of different serious reactions," said Rasmussen.

After requesting an accelerated review by the FDA, Chantix was approved for use in the U.S. in May, 2006. Chantix revenues hit $883 million in 2007, according to corporate performance reports available on the company's website. The Institute for Safe Medication report, cited in the FAA's ban on Chantix use among pilots and air traffic controllers, is the latest in a serious of reports highlighting concerns about the drug. In November, 2007, the U.S. Food and Drug Administration released a Preliminary Assessment specifically highlighting the number of reports noting an association between suicide and attempted suicide within days to weeks of initiating Chantix treatment.

On February 1, 2008, public health concerns intensified when the FDA issued a Public Health Advisory stating that "Serious neuropsychiatric symptoms have occurred in patients taking Chantix." Symptoms outlined include changes in behavior, agitation, depressed mood, suicidal ideation, and attempted and completed suicide. Rasmussen says more studies are likely as attorneys move forward with litigation.

About Cory Watson Crowder & DeGaris

Cory Watson Crowder & DeGaris is recognized nationally for its practice in mass torts litigation, multidistrict litigation and complex litigation including class actions, products liability, business and securities litigation, environmental litigation and mass torts litigation of defective medical devices and pharmaceuticals.


'/>"/>
SOURCE Cory Watson Crowder & DeGaris
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Warner Chilcott Announces Settlement of Securities Litigation
2. Seattle-Based Law Firm Williams Kastner Receives Significant Defense Verdict in Trade Secret Business Litigation Case
3. KV Pharmaceutical Company Announces Proposed Settlement in Principle of Derivative Shareholder Litigation
4. Retail Industry Leaders Association Files Amicus in California Health Care Litigation
5. Peter Burg Appointed as Co-Chair of the Plaintiffs Steering Committee and the Executive Committee for the Gadolinium-Based Contrast Agents Product Liability Multi-District Litigation
6. Hagens Berman Sobol Shapiro: Nationwide Class Action Certified in Average Wholesale Price Litigation
7. MedQuist Announces Entry Into Settlement Term Sheet Resolving South Broward Litigation
8. Hagens Berman: Eleven Defendants Settle in Average Wholesale Price Litigation
9. Information About The Airborne Health, Inc. Settlement, and Other Ongoing Litigation Alleging False and Deceptive Marketing Of Airborne(R)
10. Anapol Schwartz Attorney Representing Trasylol(R) Victims Says Medical Study - Confirming Heart Bypass Drug Mortality Risk - to Open Floodgates for More Litigation
11. 60 Minutes to Report on Dangers of Trasylol: Cory Watson Crowder & DeGaris Involved in Litigation Against Pharmaceutical Giant Bayer AG
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... 27, 2016 , ... Quality metrics are proliferating in cancer care, and are ... the eye of the beholder, according to experts who offered insights and commentary in ... Managed Care. For the full issue, click here . , For the American ...
(Date:6/26/2016)... ... ... Brent Kasmer, a legally blind and certified personal trainer is helping to develop a weight ... app plans to fix the two major problems leading the fitness industry today:, ... program , They don’t eliminate all the reasons people quit their exercise program ...
(Date:6/25/2016)... ... ... closing of Bruton Memorial Library on June 21 due to a possible lice infestation, as ... of head lice: the parasite’s ability to live away from a human host, and to ... one in the event that lice have simply gotten out of control. , As lice ...
(Date:6/25/2016)... City, Oklahoma (PRWEB) , ... June 25, 2016 ... ... helping both athletes and non-athletes recover from injury. Recently, he has implemented orthobiologic ... the Oklahoma City area —Johnson is one of the first doctors to perform ...
(Date:6/24/2016)... Marne, Michigan (PRWEB) , ... June 24, 2016 , ... ... To deal with these feelings, many turn to unhealthy avenues, such as drug or ... Center of Marne, Michigan, has released tools for healthy coping following a traumatic event. ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... --  Pulmatrix, Inc ., (NASDAQ: PULM ), ... today that it was added to the Russell Microcap ... set of U.S. and global equity indexes on June ... for Pulmatrix," said Chief Executive Officer Robert Clarke ... in developing drugs for crucial unmet medical needs, and ...
(Date:6/23/2016)... HILLS, Calif. , June 23, 2016 Any ... the many challenges of the current process. Many of them ... because of the technical difficulties and high laboratory costs involved. ... have to offer it at such a high cost that ... afford it. Dr. Parsa Zadeh , founder ...
(Date:6/23/2016)... LOS ANGELES , June 23, 2016 /PRNewswire/ ... (NASDAQ: CAPR ), a biotechnology company ... first-in-class therapeutics, today announced that patient enrollment in ... progrEssion in Duchenne) has exceeded 50% of its ... its enrollment in the third quarter of 2016, ...
Breaking Medicine Technology: